Details of the Drug Pharmacogenomic Perturbation Atlas

Varenicline Drug Info

CP 526555; Champix (TN); Chantix (TN); Varenicline (INN); 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline

Cross-matching ID

PubChem CID

170361

CAS Number

CAS 249296-44-4

TTD Drug ID

D0LM4A

VARIDT Drug ID

DR00237

ACDINA Drug ID

D00722

General Information of Drug (ID: DMMUOLJ)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.22	0.00e+0	34/36 (94.44%)	RFC3;PCNA;POLE2;...
Mismatch repair	2.20	0.00e+0	22/23 (95.65%)	RFC3;PCNA;MSH2;...
Nucleotide excision repair	2.03	3.36e-3	40/47 (85.11%)	RFC3;RBX1;PCNA;...
Proteasome	2.00	5.05e-3	44/46 (95.65%)	PSMB3;PSMF1;PSME1;...
Cell cycle	1.92	6.05e-3	110/124 (88.71%)	CCNA2;MAD2L1;CHEK1;...
Graft-versus-host disease	1.84	1.68e-2	32/42 (76.19%)	HLA-DQA1;FAS;TNF;...
Steroid biosynthesis	1.79	2.59e-2	19/20 (95%)	DHCR24;MSMO1;SOAT1;...
Inflammatory bowel disease	1.76	3.28e-2	58/65 (89.23%)	HLA-DQA1;TLR4;GATA3;...
Allograft rejection	1.76	3.03e-2	32/38 (84.21%)	HLA-DQA1;FAS;TNF;...
Type I diabetes mellitus	1.76	2.93e-2	38/43 (88.37%)	HLA-DQA1;FAS;TNF;...
Oxidative phosphorylation	1.74	3.03e-2	93/133 (69.92%)	NDUFV2;ATP5PD;COX7B;...
Base excision repair	1.71	3.70e-2	29/33 (87.88%)	POLB;PCNA;POLE2;...
Asthma	1.71	3.65e-2	25/31 (80.65%)	HLA-DQA1;FCER1A;TNF;...
Ribosome	1.71	3.53e-2	113/158 (71.52%)	MRPS16;RPL26L1;MRPL17;...
Huntington disease	1.71	3.30e-2	233/306 (76.14%)	PSMB3;NDUFV2;HDAC2;...
ECM-receptor interaction	-1.95	2.97e-2	80/88 (90.91%)	ITGA3;THBS2;ITGB1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H